ZOLL LifeVest

What ZOLL LifeVest does

ZOLL LifeVest is the wearable cardioverter defibrillator (WCD) franchise of ZOLL Medical Corporation, a wholly-owned subsidiary of Japanese conglomerate Asahi Kasei (TSE: 3407) since 2012. The company develops and commercializes the LifeVest WCD — the world's first and most clinically studied wearable defibrillator, with over 20 years of clinical use and more than one million patients supported — which continuously monitors heart rhythm and delivers automated defibrillation for patients at risk of sudden cardiac death. The fifth-generation LifeVest, launched in December 2025, incorporates AI-based safety components and pairs with a redesigned comfort garment backed by peer-reviewed compliance data.

The broader portfolio addresses adjacent cardiac care needs: the Heart Failure Management System (HFMS) provides remote monitoring to reduce hospital readmissions, TherOx SuperSaturated Oxygen Therapy treats post-cardiac-event patients to reduce heart failure risk, the WatchPAT Home Sleep Apnea Test is offered through a partnership with Itamar Medical, and the newly approved Zenix Monitor/Defibrillator targets EMS and hospital critical-care settings following FDA (October 2025) and MDR (February 2026) approvals. The ZOLL Patient Management (ZPM) Network serves as the operational backbone for patient enrollment, device delivery, and ongoing monitoring across U.S. and international markets.

The business model is hardware-sales driven, with quote-based pricing and insurance reimbursement-mediated revenues flowing through direct sales to cardiologists, electrophysiologists, hospitals, and clinics across 10+ countries. Distribution is supported by localized websites and regional offices, supplemented by a community-level ecosystem buildout via the PulsePoint Foundation's National Emergency AED Registry (200,000+ registered AEDs). Recent strategic emphasis is on portfolio diversification (Zenix), continued AI-enabled product upgrades (fifth-generation WCD), and geographic expansion into Europe via MDR approval.

Name

ZOLL LifeVest

Legal name

ZOLL Medical Corporation

Website

https://lifevest.zoll.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

ZOLL LifeVest, a ZOLL Medical Corporation brand under Asahi Kasei, develops the world's first wearable cardioverter defibrillator and adjacent cardiac care products, serving at-risk cardiac patients, heart failure patients, and prescribing cardiologists across 10+ countries.

Ownership category

akta.pro rank

Product category

Cardiac Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)

akta.pro secondary industries

Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB), Cardiac Rhythm Management (Pacemakers, ICDs, CRT) (HLAHAFAC)

Keywords

• Wearable defibrillator devices
• Cardiac patient monitoring
• Heart failure management
• Remote cardiac monitoring
• Emergency cardiac care

Headquarters

HQ city

Pittsburgh

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Supply Chain, Marketing or Sales, Personnel

Revenue model

1. LifeVest Wearable Defibrillator Device Sales: Medical device sales to healthcare providers and directly to patients through physician prescription. The device is provided as a wearable therapeutic solution for at-risk cardiac patients.
2. Heart Failure Management System (HFMS): Remote monitoring system for heart failure patients to reduce readmissions through early intervention and management.
3. TherOx SuperSaturated Oxygen Therapy: Therapeutic oxygen treatment system for reducing heart failure risk in hospital settings.
4. WatchPAT Home Sleep Apnea Test: Home-based sleep apnea diagnostic testing through partnership with Itamar Medical.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

ZOLL LifeVest develops and manufactures the LifeVest wearable cardioverter defibrillator (WCD) and related cardiac patient management solutions. The portfolio provides continuous 24/7 cardiac rhythm monitoring with automated defibrillation therapy for patients at risk of sudden cardiac death, alongside heart failure remote monitoring, super-saturated oxygen therapy, and home sleep apnea diagnostics.

Product overview

ZOLL LifeVest offers a cardiac patient management portfolio centered on the LifeVest Wearable Cardioverter Defibrillator (WCD) as its flagship product, supported by the Heart Failure Management System (HFMS) for remote monitoring and readmission reduction. The portfolio includes TherOx SuperSaturated Oxygen Therapy for post-cardiac event treatment, WatchPAT Home Sleep Apnea Test for diagnostic testing, and the ZOLL Patient Management (ZPM) Network for care coordination. The Zenix Monitor/Defibrillator serves acute care settings. The company has protected over 1 million patients across more than 20 years, with the fifth-generation LifeVest recently launched featuring AI-powered safety components.

Differentiator

Problem solved

Functional benefit

Brands

• LifeVest: World's first wearable cardioverter defibrillator (WCD) designed to monitor and protect patients at risk of sudden cardiac death.
• Heart Failure Management System (HFMS)
• TherOx SuperSaturated Oxygen Therapy
• WatchPAT
• ZOLL Patient Management (ZPM) Network

Products and services

• LifeVest Wearable Cardioverter Defibrillator (WCD) A wearable cardioverter defibrillator that continuously monitors heart rhythm and delivers shock therapy when life-threatening arrhythmias are detected. Prescribed to at-risk cardiac patients post-myocardial infarction, with cardiomyopathy, or awaiting permanent ICD implantation. Has protected over 1 million patients with more than 20 years of clinical use.
• Heart Failure Management System (HFMS)

Quantifiable outcome

• Over 1 million patients protected with LifeVest WCD
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• PulsePoint FoundationcoreStrategic or Co-development Partner · 1 December 2025The PulsePoint Foundation and ZOLL announced the 'Anyone Can Register' initiative in December 2025 to expand the National Emergency AED Registry (NEAR). The program aims to increase the number of registered AEDs from the current 200,000+ by mobilizing volunteers, AED owners, and manufacturers to locate and add AEDs across the country. Launching in February 2026, the initiative promotes the PulsePoint AED app for community engagement and device registration to improve emergency response and save lives.
• Asahi KaseicoreStrategic or Co-development Partner · 1 October 2025Asahi Kasei, the parent company of ZOLL Medical Corporation, obtained FDA approval for ZOLL's Zenix monitor/defibrillator in the U.S., expanding its critical care product lineup. The Zenix device is designed for EMS and hospital settings with advanced features including large touchscreen and real-time adjustments.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Kestra Medical Technologies: Kestra Medical Technologies is an emerging direct competitor developing wearable cardioverter defibrillator technology targeting the same at-risk cardiac patient population that ZOLL LifeVest serves, making it the most directly comparable peer.
• Defibtech: Defibtech manufactures AEDs and defibrillator products that compete with ZOLL's EMS and hospital defibrillator lines, including the newly launched Zenix monitor/defibrillator.

Broad incumbents

• Medtronic: Medtronic is the global leader in implantable cardiac devices including ICDs, CRTs, and cardiac monitoring—directly competing with LifeVest's bridge therapy use case and serving the same cardiology customer base.
• Boston Scientific: Boston Scientific is a major incumbent in cardiac rhythm management with ICD, CRT, and remote cardiac monitoring products that compete with and serve as the downstream destination for LifeVest patients.
• Abbott: Abbott's cardiac rhythm management division (including the CardioMEMS HF System) competes directly with ZOLL's Heart Failure Management System and shares the same cardiology prescribing channel.
• Philips: Philips HeartStart AEDs and cardiac monitoring portfolio overlap with ZOLL's emergency cardiac response and EMS product lines, including the recently approved Zenix monitor/defibrillator.
• Baxter International: Baxter's critical care portfolio, including patient monitoring and cardiac care products, overlaps with ZOLL's hospital-based offerings such as TherOx SSO2 Therapy and Zenix monitor/defibrillator.

Emerging players

• iRhythm Technologies: iRhythm's Zio long-term cardiac monitoring patch competes with LifeVest in ambulatory cardiac arrhythmia detection and serves overlapping cardiology and electrophysiology customers.
• Element Science: Element Science is developing next-generation wearable cardiac devices targeting similar at-risk patient populations, representing an emerging competitive threat to LifeVest's wearable defibrillator category.
• Itamar Medical: Itamar Medical's WatchPAT home sleep apnea test is distributed through ZOLL but the company operates its own competitive sleep diagnostics business with overlap in the cardiac-sleep patient population.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/zoll-medical-corporation

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ZOLL LifeVest